AI Provisions in Healthcare APAs: Allocating Risk in the Age of Clinical Algorithms

When the target company's value rests on an algorithm that touches patient care, the standard healthcare acquisition agreement quietly stops being adequate. The reps were written for a world of EHRs and billing software — not for models that make, or shape, clinical decisions.

AI has moved from a footnote in healthcare deals to a core value driver: clinical decision support, diagnostic imaging models, ambient documentation, revenue-cycle automation, patient-triage tools. Buyers are paying for the model and the data behind it. But a clinical algorithm carries a risk profile that a generic intellectual-property representation doesn't capture — regulatory classification, training-data provenance, bias and performance, and professional-liability exposure all sit inside the asset. Allocating that risk is now its own workstream in the purchase agreement.

Start with diligence — the reps are only as good as what they're built on

Before drafting a single rider, the diligence request list should surface the facts the representations will stand on:

• Regulatory status. Is any tool a medical device? Has the target taken a Software-as-a-Medical-Device (SaMD) position, sought FDA clearance, or relied on an enforcement-discretion or exemption theory? Get the written analysis, not the conclusion.
• Training-data provenance. Where did the data come from, what consents and licenses cover it, was it properly de-identified, and does any of it carry HIPAA or contractual use restrictions that survive the deal?
• Performance and validation. Validation studies, accuracy/bias testing, known failure modes, and post-deployment monitoring. Undisclosed performance degradation is a classic latent liability.
• Third-party model dependencies. Foundation models, APIs, and open-source components — with their license terms and any restrictions on commercial or clinical use.
• Human oversight. How the tool is positioned relative to clinician judgment, and what the target tells customers and regulators about that line.

Seller-side representations to expect (and negotiate)

A buyer will push for AI-specific reps beyond the boilerplate IP and compliance sections. Sellers should expect — and carefully qualify — representations addressing:

• Regulatory compliance of each AI tool, including FDA/SaMD status and the absence of undisclosed agency communications;
• Ownership of (or sufficient license to) all training data, model weights, and outputs, free of infringing or improperly sourced inputs;
• Compliance of data practices with HIPAA and applicable privacy law, including business-associate obligations;
• Validation, performance, and the absence of known material defects or bias issues; and
• Disclosure of all open-source and third-party components and their license terms.

Sellers protect themselves with knowledge qualifiers, materiality thresholds, and a disclosure schedule that does real work — an accurate schedule is often a better shield than negotiating the rep itself down to nothing.

Indemnities, carve-outs, and the RWI overlay

This is where AI deals most often diverge from standard structures. Because the exposures (regulatory enforcement, IP infringement in training data, privacy violations) can be large, latent, and slow to surface, buyers frequently seek special indemnities for defined AI risks — sitting outside the general cap and survival period, sometimes backed by a dedicated escrow.

Representation and warranty insurance (RWI) complicates the picture. Insurers increasingly scrutinize AI exposures and may exclude them, condition coverage on diligence depth, or carve out specific risks (training-data IP, regulatory classification). The drafting has to align three documents at once: what the reps say, what RWI will actually cover, and what the special indemnities and escrow catch in the gap the policy leaves open. A rep that the buyer believes is insured — but isn't — is a trap for both sides.

In an AI healthcare deal, the question isn't only "is the representation true?" It's "if it's wrong, who pays, from which pot, and did the insurer already carve that exact risk out?"

Don't forget the regulatory triangle underneath

AI doesn't suspend the rest of healthcare law. If the tool influences referrals, ordering, or utilization, the Anti-Kickback Statute and Stark analysis still applies; if it shapes clinical decisions, the corporate-practice-of-medicine line and professional-liability allocation matter; and any patient data flowing through it lives under HIPAA. The AI rider should be drafted as a layer on top of the deal's existing fraud-and-abuse and privacy framework, not as a replacement for it.

The deals that close cleanly are the ones where the AI was treated as what it is — a regulated clinical asset with its own diligence, its own representations, and its own risk-allocation logic — rather than bolted onto a template written for a quieter generation of healthcare software.